FeesSafety
Pluang+

Oppenheimer hires Patrick McCarthy to lead new defense tech research amid AI and robotics advances

Market News
03 Nov 2026, 13:00 WIB
PRNewsWire
View Source
Bullish
Oppenheimer hires Patrick McCarthy to lead new defense tech research amid AI and robotics advances

Oppenheimer & Co. has appointed Patrick McCarthy as Managing Director to lead its new defense research coverage focused on defense technology and national security, including AI, drones, and robotics. This move supports clients in understanding investment opportunities as military tech evolves rapidly with advances in autonomy and precision. McCarthy brings over 25 years of experience in defense research and banking, enhancing Oppenheimer's expertise alongside recent hires in aerospace and defense investment banking. The initiative reflects growing importance of innovation in defense and national security sectors for investors.

Oppenheimer's launch of defense coverage with Patrick McCarthy comes as a backdrop to the Industrials sector on Pluang, where out of 135 US stocks, 72 rose and 53 fell as of Nov 03, 2026 17:41 WIB. Notable movers include Canadian National Railway Co. (CNI) at USD 123.84 with a 1-day change of -2.32% and a typical hold time of 105 days, Eos Energy Enterprises Inc (EOSE) at USD 1.80 with a 1-day change of +2.27% and 80% buy order activity, and BWX Technologies (BWXT) at USD 127.81 with a 1-day change of -2.04% and a typical hold time of 19 days.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
1 hour ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
1 hour ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
1 hour ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
2 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App